ReviewJournal of gastroenterology2010
New pathophysiological insights and modern treatment of IBD.
Review in Journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it, 189 citations in OpenAlex.
- Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease.Virchows Archiv : an international journal of pathology · 2021Guideline
- Article
- Role of PD-L1 in mediating the effect of lipid on ulcerative colitis: a mediation Mendelian randomization study.Frontiers in genetics · 2025Article
- Sea conch (Food science & nutrition · 2024Article
- Pathologically catalyzed physical coating restores the intestinal barrier for inflammatory bowel disease therapy.Journal of nanobiotechnology · 2023Article
- Sea Conch Peptides Hydrolysate Alleviates DSS-Induced Colitis in Mice through Immune Modulation and Gut Microbiota Restoration.Molecules (Basel, Switzerland) · 2023Article
- The role of phosphatidylcholine 34:1 in the occurrence, development and treatment of ulcerative colitis.Acta pharmaceutica Sinica. B · 2023Article
- Electrical neuromodulation therapy for inflammatory bowel disease.World journal of gastrointestinal pathophysiology · 2022Review
- A polyphenol-assisted IL-10 mRNA delivery system for ulcerative colitis.Acta pharmaceutica Sinica. B · 2022Article
- Chronic Experimental Model of TNBS-Induced Colitis to Study Inflammatory Bowel Disease.International journal of molecular sciences · 2022Article
- Novel Psychoactive Substances: The Razor's Edge between Therapeutical Potential and Psychoactive Recreational Misuse.Medicines (Basel, Switzerland) · 2022Review
- Nuciferine Regulates Immune Function and Gut Microbiota in DSS-Induced Ulcerative Colitis.Frontiers in veterinary science · 2022Article
- Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.European journal of pediatrics · 2021Observational
- Inflammation- and Gut-Homing Macrophages, Engineered toInternational journal of molecular sciences · 2021Article
- Systems pharmacology approach uncovers Ligustilide attenuates experimental colitis in mice by inhibiting PPARγ-mediated inflammation pathways.Cell biology and toxicology · 2021Article
- Bile Acids and Microbiota: Multifaceted and Versatile Regulators of the Liver-Gut Axis.International journal of molecular sciences · 2021Review
- A Review of Hyperbaric Oxygen Therapy for Inflammatory Bowel Disease.International journal of general medicine · 2021Review
- Indeterminate Colitis - Update on Treatment Options.Journal of inflammation research · 2021Review
- Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study.PloS one · 2021Article
- Treatment of Intestinal Inflammation With Epicutaneous Immunotherapy Requires TGF-β and IL-10 but Not Foxp3Frontiers in immunology · 2021Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), which comprises two main types, namely, Crohn's disease and ulcerative colitis, affects approximately 3.6 million people in the USA and Europe, and an alarming rise in low-incidence areas, such as Asia, is currently being observed. In the last decade, spontaneous mutations in a diversity of genes have been identified, and these have helped to elucidate pathways that can lead to IBD. Animal studies have also increased our knowledge of the pathological dialogue between the intestinal microbiota and components of the innate and adaptive immune systems misdirecting the immune system to attack the colon. Present-day medical therapy of IBD consists of salicylates, corticosteroids, immunosuppressants and immunomodulators. However, their use may result in severe side effects and complications, such as an increased rate of malignancies or infectious diseases. In clinical practice, there is still a high frequency of incomplete or absent response to medical therapy, indicating a compelling need for new therapeutic strategies. This review summarizes current epidemiology, pathogenesis and diagnostic strategies in IBD. It also provides insight in today's differentiated clinical therapy and describes mechanisms of promising future medicinal approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.